The Acute Lung Injury market report also offers comprehensive insights into the Acute Lung Injury market size, share, Acute Lung Injury epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Acute Lung Injury market size growth forward.
Some of the key highlights from the Acute Lung Injury Market Insights Report:
Several key pharmaceutical companies, including Asklepion Pharmaceuticals, LLC, Edesa Biotech, Direct Biologics, and others, are developing novel products to improve the Acute Lung Injury treatment outlook.
In December 2024, the U.S. Food and Drug Administration (FDA) approved EB05, a toll-like receptor 4 (TLR4) inhibitor, for the treatment of ALI. TLR4 plays a pivotal role in mediating inflammation associated with ALI, especially in cases triggered by viral infections like SARS-CoV-2 and Influenza. Clinical trials demonstrated that EB05 effectively reduced inflammation and improved lung function in patients with ALI, marking a significant advancement in therapeutic options.
Recent research has focused on the reactive oxygen species (ROS)/NLRP3 inflammasome pathway, which contributes to inflammation and cell death in ALI. Studies have shown that inhibiting this pathway can protect against lipopolysaccharide (LPS)-induced ALI by reducing ROS/NLRP3-dependent pyroptosis and apoptosis through the Nrf2 signaling pathway. These findings offer promising avenues for developing targeted therapies that address the underlying mechanisms of ALI.
The Acute Lung Injury market is projected to expand, driven by factors such as the rising incidence of the condition, increased awareness among healthcare professionals, and advancements in both diagnostics and treatment options.
The emergence of the COVID-19 pandemic led to a substantial increase in cases of ARDS across the 7MM, further contributing to the market’s growth.
Determining the exact market size remains challenging due to the diverse nature of Acute Lung Injury and its overlap with acute respiratory distress syndrome (ARDS). Nevertheless, the market is anticipated to witness steady growth as the incidence of the condition continues to rise.
Key players in the Acute Lung Injury market, including Asklepion Pharmaceuticals, LLC, Edesa Biotech, and Direct Biologics, have been actively developing assets within this evolving space. However, the market faces challenges due to the complexity of the condition, the need for personalized treatment strategies, and the high costs associated with research and development.
Acute lung injury therapies are Neuromuscular Blocking Agents (NMBAs), Inhaled Vasodilators, Corticosteroids, and others.
As per DelveInsight analysis, the Acute Lung Injury market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Acute Lung Injury Market Landscape
Acute Lung Injury Overview
Acute Lung Injury (ALI) is a condition marked by lung inflammation and damage, leading to compromised gas exchange and respiratory failure. It represents a severe form of lung impairment and can arise from various factors such as infections, trauma, exposure to toxic substances, and sepsis. The American–European Consensus Conference established specific criteria to define ALI and Acute Respiratory Distress Syndrome (ARDS) in both clinical practice and research. The distinction between ALI and ARDS is based on the severity of hypoxemia, measured by the ratio of arterial oxygen partial pressure to inspired oxygen fraction (PaO₂/FiO₂), with ALI exhibiting a less severe degree of hypoxemia compared to ARDS.
Do you know the treatment paradigms for different countries? Download our Acute Lung Injury Market Sample Report
Acute Lung Injury Epidemiology Insights
Bellani et al. (2016) conducted a multicenter prospective study across 459 ICUs in 50 countries spanning five continents. Their findings revealed that ARDS accounted for 10.4% of all ICU admissions and 23.4% of patients requiring mechanical ventilation. Among ARDS cases, 30.0% were classified as mild, 46.6% as moderate, and 23.4% as severe. The overall unadjusted mortality rates in the ICU and hospital were 35.3% and 40.0%, respectively.
Acute Lung Injury Epidemiology Segmentation
DelveInsight’s Acute Lung Injury market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Acute Lung Injury historical patient pools and forecasted Acute Lung Injury patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Acute Lung Injury Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Acute Lung Injury Prevalence
Age-Specific Acute Lung Injury Prevalence
Gender-Specific Acute Lung Injury Prevalence
Diagnosed and Treatable Cases of Acute Lung Injury
Visit for more @ Acute Lung Injury Epidemiological Insights
Acute Lung Injury Market Outlook
The current treatment strategy for ALI focuses on supportive care, addressing the underlying cause (e.g., infections or sepsis), and managing complications. This includes administering antibiotics, corticosteroids, and anti-inflammatory medications. However, existing therapies primarily target inflammation and do not directly restore lung function, highlighting a significant need for new treatments.
Several randomized controlled trials have explored pharmacological interventions for ALI, but no definitive treatment has been successful. Research is ongoing into mechanisms such as inhibiting the ROS/NLRP3 pathway, which may protect against ALI by preventing inflammation-induced cell death. EB05, a toll-like receptor 4 (TLR4) inhibitor, has gained attention for its potential role in treating ALI, particularly in cases triggered by viral infections like SARS-CoV-2 and Influenza.
Emerging therapies are investigating novel pharmacological agents that target specific inflammatory pathways, including anti-inflammatory cytokines, antioxidants, and immunomodulators. Additionally, advancements in precision medicine and personalized approaches may lead to more effective, tailored treatments for ALI in the future.
Acute Lung Injury Emerging Drugs
L-citrulline: Asklepion Pharmaceuticals, LLC
EB05: Edesa Biotech
Acute Lung Injury Key Companies
Asklepion Pharmaceuticals, LLC, Edesa Biotech, Direct Biologics, and others
For more information, visit Acute Lung Injury Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Acute Lung Injury Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Acute Lung Injury, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Acute Lung Injury epidemiology in the 7MM
Acute Lung Injury marketed and emerging therapies
Acute Lung Injury companies
Acute Lung Injury market drivers and barriers
Table of Contents:
1 Acute Lung Injury Market Key Comprehensive Insights
2 Acute Lung Injury Market Report Introduction
3 Competitive Intelligence Analysis for Acute Lung Injury
4 Acute Lung Injury Market Analysis Overview at a Glance
5 Executive Summary of Acute Lung Injury
6 Acute Lung Injury Epidemiology and Market Methodology
7 Acute Lung Injury Epidemiology and Patient Population
8 Acute Lung Injury Patient Journey
9 Acute Lung Injury Treatment Algorithm, Acute Lung Injury Current Treatment, and Medical Practices
10 Key Endpoints in Acute Lung Injury Clinical Trials
11 Acute Lung Injury Marketed Therapies
12 Acute Lung Injury Emerging Therapies
13 Acute Lung Injury: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Acute Lung Injury
16 Acute Lung Injury Market Key Opinion Leaders Reviews
18 Acute Lung Injury Market Drivers
19 Acute Lung Injury Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Acute Lung Injury Epidemiology 2032
DelveInsight’s “Acute Lung Injury – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Acute Lung Injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Acute Lung Injury Pipeline 2024
“Acute Lung Injury Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Lung Injury market. A detailed picture of the Acute Lung Injury pipeline landscape is provided, which includes the disease overview and Acute Lung Injury treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
